MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00198-026-08178-0

Медицинская библиотека · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026

Clinical guidance on evaluation and management of bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS): an IOF position statement.

Confavreux Cyrille B, Bouvard Beatrice, Blank Robert, Hadji Peyman, Biver Emmanuel, Body Jean-Jacques, Brandi Maria Luisa, Campusano Claudia, Ebeling Peter R, Maghraoui Abdellah El, Holzer Gerold, Kendler David, de Villiers Tobie, Rizzoli René, Foldes A Joseph

СтатьяПеревод в очереди

Аннотация

UNLABELLED: Monoclonal gammopathy of undetermined significance (MGUS) is a frequent hematological condition that occurs in later life. MGUS is associated with increased fragility fractures that mix individual osteoporotic risk factors, MGUS-related comorbidities, and direct MGUS bone impact such as senescence of plasma cells. This International Osteoporosis Foundation (IOF) position statement aims at evaluating the potential relationship between MGUS and fracture risk, as well as methods for evaluating bone involvement in MGUS. Finally, we propose the first bone clinical guidance for patients with MGUS to improve their bone health.

BACKGROUND

Monoclonal gammopathy of undetermined significance is a prevalent hematological condition in adults, characterized by the presence of an abnormal monoclonal protein in the blood without concomitant symptoms or malignancy. MGUS is of considerable bone significance and contributes to fragility fractures in adults.

METHODS

In this review, data pertaining to bone fragility were collected, including epidemiological fracture data in patients with MGUS, bone mineral density (BMD), bone microarchitecture, bone turnover marker, and bone histomorphometry data.

RESULTS

Collectively, these findings suggest an elevated risk of fractures, especially in presence of osteoporotic risk factors or comorbidities, and a diminished BMD due to augmented bone resorption. Studies focusing on the treatment of this condition are limited.

CONCLUSION

Based on this analysis, we present the International Osteoporosis Foundation (IOF) position statement for bone evaluation and management of these patients. We recommend a risk-adapted treatment strategy. A proposal of bone clinical guidance dedicated to patients with MGUS is presented, suggesting bisphosphonates as the preferred treatment option.

Для цитирования: Confavreux Cyrille B, Bouvard Beatrice, Blank Robert, Hadji Peyman, Biver Emmanuel, Body Jean-Jacques, Brandi Maria Luisa, Campusano Claudia, Ebeling Peter R, Maghraoui Abdellah El, Holzer Gerold, Kendler David, de Villiers Tobie, Rizzoli René, Foldes A Joseph. Clinical guidance on evaluation and management of bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS): an IOF position statement.. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2026. DOI: 10.1007/s00198-026-08178-0.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.